USD10
SVRA Shares
About SavaraSavara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
USD10
SVRA Shares
About SavaraSavara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Stats
TRADING WINDOW
Closed
OPENS AT
Sep 1 at 1:30 PM GMT+0
MARKET CAP
$1.11B
OPEN PRICE
Not enough data
LOW (1Y)
$3.21
HIGH (1Y)
$7.01
LOW (24H)
$5.21
HIGH (24H)
$5.51
VOLUME (24H)
$234.00
99.99%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $5.36 | |
1 Week | $5.59 | |
1 Month | $5.58 | |
1 Year | $3.31 |
Past performance is not a reliable indicator of future results.
Discover more
Learn how to buy popular cryptocurrencies
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.